<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) remain challenging to the clinician in terms of diagnosis and management </plain></SENT>
<SENT sid="1" pm="."><plain>The diagnosis is essentially one of exclusion in first ruling out other disorders that can also cause peripheral blood/bone marrow cell <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and cytopenias </plain></SENT>
<SENT sid="2" pm="."><plain>Recent studies implicate extensive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> as the explanation of the paradoxical observation of marrow <z:mpath ids='MPATH_134'>hyperplasia</z:mpath>, but peripheral blood cytopenia </plain></SENT>
<SENT sid="3" pm="."><plain>The clonal nature of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> places it also at continual risk for transformation to <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Predicting overall survival as well as the risk of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) transformation has been improved by the development of the International Prognostic Scoring System (IPSS) </plain></SENT>
<SENT sid="5" pm="."><plain>Management of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> can now be based on the patients respective prognostic subgrouping </plain></SENT>
<SENT sid="6" pm="."><plain>Low-risk patients should be considered for hematopoietic growth factor singly or in combination, while high-risk patients should be offered <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-induction therapy or novel therapeutic agents </plain></SENT>
<SENT sid="7" pm="."><plain>Common complications are <z:hpo ids='HP_0001875'>neutropenias</z:hpo> with <z:hpo ids='HP_0002719'>recurrent infections</z:hpo> and red cell transfusion dependence </plain></SENT>
<SENT sid="8" pm="."><plain>Future advances upon understanding the molecular details of the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone should ultimately improve the care of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>